Dermatology 2013

Moreno, J C

Notario, J

Rivera, R

Rodriguez-Cerdeira, C

Romero, A

Ruiz-Villaverde, R

Taberner, R

Vidal, D

eng

Consensus Development Conference

Practice Guideline

Spain

2013/09/11 06:00

Actas Dermosifiliogr. 2013 Oct;104(8):694-709. doi: 10.1016/j.adengl.2013.04.013. Epub 2013 Sep 7.

URL: http://www.ncbi.nlm.nih.gov/pubmed/24018211

Author Address: Servicio de Dermatologia, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain. Electronic address: lpuig@santpau.cat.

 

 

Reference Type:  Journal Article

Record Number: 4289Author: Rabasseda, X.

Year: 2013

Title: A report from the 22nd Congress of the European Academy of Dermatology and Venereology (October 2-6, 2013 – Istanbul, Turkey)

Journal: Drugs Today (Barc)

Volume: 49

Issue: 10

Pages: 667-77

Date: Oct

Short Title: A report from the 22nd Congress of the European Academy of Dermatology and Venereology (October 2-6, 2013 – Istanbul, Turkey)

Alternate Journal: Drugs of today

ISSN: 1699-3993 (Print)

1699-3993 (Linking)

DOI: 10.1358/dot.2013.49.10.2076505

Accession Number: 24191258

Keywords: Dermatitis, Atopic/drug therapy

Humans

Melanoma/drug therapy

Psoriasis/drug therapy

Skin Diseases/*drug therapy

Skin Neoplasms/drug therapy

Abstract: During the annual congress of the European Academy of Dermatology and Venereology (EADV), Istanbul, a bridge across Europe and Asia, attracted dermatologists from both continents, along with researchers and clinicians from the Americas and other parts of the world, to discuss new advancements in the treatment of common, in many cases severe, diseases that affect not only the skin, but also deep into human bodies. The following report reflects the important fact in dermatology that biologic and targeted therapies are conquering the drug armamentarium well beyond the known area of psoriasis and melanoma into areas such as atopic dermatitis. In fact, early clinical trials with two novel monoclonal antibodies presented during the first day of scientific sessions at EADV demonstrated a favorable efficacy profile that anticipates innovative developments in the strategies for treating atopic dermatitis and possibly other diseases of the skin. Many other topics of interest were also discussed during the meeting’s sessions and electronic poster presentations, as summarized in the report.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295